American CryoStem Announces "ACS Laboratory Services"
January 13 2012 - 9:00AM
Marketwired
American CryoStem Corporation (OTCBB: CRYO) announces the branding
of "ACS Laboratory Services."
As of January 2012 we have branded our adipose tissue processing
facility "ACS Laboratory Services." This new branding reflects the
Company's increasing commercialization of products and services
developed for its proprietary clinical tissue processing
methodologies. We have begun offering the first of these products
for sale and license which are based on our granted patent (Cell
Culture Media, Kits and Methods of Use," (US 7,898,205 B2)). The
product line is the first patented culture, growth and
differentiation media specifically designed for use with adipose
derived stem cells (ADSC) and is ideally suited for the conversion
of new ADSC therapies from research to clinical application. The
media is available in both research and clinical grade, in 100ml to
1 liter ready to use quantities. The product line includes
undifferentiated growth media, and adipogenic, chondrogenic, and
osteogenic differentiation media. The clinical grade media are free
from animal (xenomorphic) serum and additives which make them
ideally suited for the expansion and differentiation of ADSCs
intended for clinical use.
We made our first commercial sale of our media products this
month and have begun marketing to increase industry recognition and
sales. We currently have a new website www.acslaboratories.com
under construction to support this new product offering and all
future products and services commercialized by ACS
Laboratories.
David Moscatello, Chief Scientist, stated, "I am very excited to
have begun offering these products to my colleagues working with
ADSCs and believe that these products will assist them in the
acceleration of their treatment development. We have additional
products and services in various stages of development based on our
patented technologies and core adipose tissue processing platform
that will be unveiled during the coming year."
John S. Arnone, CEO, stated, "We are very enthusiastic to be
able to announce the commercialization and initial sales revenue
from products developed from our recently issued patent. During
2011 we have been the beneficiary of increased dialogue and
involvement from both doctors and researchers regarding our
services and products under development. Our overall philosophy
concerning the services offered by ACS Laboratories is to offer
clinical grade products that are free from animal materials that
can relieve some of the costs and the significant and increasing
regulatory burdens for developers of cellular technologies. These
burdens are evidenced in the U.S. Department of Health and Human
Services and the FDA's regulations and guidance for manufacturers
and developers in relation to the inclusion of xenomorphic (animal)
material in the manufacturing and marketing of new and existing
cellular products."
About American CryoStem: The Company
markets a core clinical processing platform for Adipose (fat)
Derived Adult Stem Cells. The Company's services provide for the
collection, processing, and cryopreservation (long term storage) of
adult stem cells, allowing healthy individuals to privately
preserve their stem cells for future use in personalized and
regenerative medicine at an affordable price. Adult Stem Cells
treatments are currently being utilized to potentially heal one's
own body of diseases and chronic conditions. The Company's
proprietary platform provides streamlined and affordable processing
and cryopreservation of Adipose Derived Stem Cells (ADSCs) and
Adipose Tissue (AT) for autologous use.
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain of the
statements contained herein, which are not historical facts, are
forward-looking statements with respect to events, the occurrence
of which involve risks and uncertainties.
These forward-looking statements may be impacted, either
positively or negatively, by various factors. Information
concerning potential factors that could affect the Company is
detailed from time to time in the Company's reports filed with the
Securities and Exchange Commission.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: American CryoStem Corporation 188 East Bergen Place,
Suite 204 Red Bank, NJ 07701 732-747-1007
www.americancryostem.com
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jul 2023 to Jul 2024